NOVONIX에 대한 매도 수량은 투자자에게 NOVONIX의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

NOVONIX (OTC:NVNXF) 주식, 공매도 수량 보고

NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration and Mining, Battery Technology, and NOVONIX Anode Materials. Graphite Exploration and Mining segment is engaged in the exploration and development of high-grade flake graphite deposits. The NOVONIX Anode Materials segment develops and manufactures battery anode materials. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Technology segment generates maximum revenue for the company.

NOVONIX Ltd

News

SHCO

Soho House Receives $9.00 Per Share Acquisition Offer From Third-Party Consortium Backed By Executive Chairman Ron Burkle And Yucaipa, Representing An 83% Premium, With Board Forming Special Committee To Evaluate Proposal

Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX&#xAE; System powered by Nano-Pulse Stimulation&#x2122; (NPS&#x2122;) technology, today announced that, on December 18, 2024, the Company's Co-Chairman and majority shareholder, Robert W. Duggan, exercised all of the warrants he acquired in the Company's 2024 rights offering, corresponding to $58.4 million totaling to 5,306,156 shares of Company common stock. Mr. Duggan also confirmed that, from December 11, 2024 through this past Friday, December 13, 2024, he has purchased an additional 156,714 shares of Pulse Biosciences. These transactions bring Mr. Duggan's current ownership in the Company to approximately 70%.

Offerings

PLSE

Pulse Biosciences,, On December 18, 2024, The Co's Co-Chairman And Majority Shareholder, Robert W. Duggan, Exercised All Of The Warrants He Acquired In The Co's 2024 Rights Offering, Corresponding To $58.4M Totaling To 5,306,156 Shares Of Company Common Stock

PTCT

PTC Therapeutics Submits NDA To FDA For Vatiquinone As Potential First Approved Therapy For Friedreich Ataxia In Children And Adults, Marking Fourth FDA Application In 2024

Telsey Advisory Group analyst Cristina Fernandez upgrades RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from Market Perform to Outperform and raises the price target from $485 to $500.

Upgrades

Price Target

Analyst Ratings

Telsey Advisory Group Upgrades RH to Outperform, Raises Price Target to $500

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">231.58</td>
<td align="right">2.94</td>
<td align="right">1.28</td>
<td>6.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">98.71</td>
<td align="right">1.01</td>
<td align="right">1.03</td>
<td>230</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">234.33</td>
<td align="right">2.09</td>
<td align="right">0.89</td>
<td>24.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.01</td>
<td align="right">0.38</td>
<td align="right">0.79</td>
<td>363.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">84.64</td>
<td align="right">0.59</td>
<td align="right">0.70</td>
<td>14.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">133.35</td>
<td align="right">0.91</td>
<td align="right">0.68</td>
<td>1.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.00</td>
<td align="right">0.24</td>
<td align="right">0.58</td>
<td>5.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.42</td>
<td align="right">0.19</td>
<td align="right">0.23</td>
<td>10.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">75.05</td>
<td align="right">0.16</td>
<td align="right">0.21</td>
<td>9.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">137.54</td>
<td align="right">0.22</td>
<td align="right">0.16</td>
<td>14.3K</td>
</tr>
</tbody>
</table>
No loser in today's Pre-market session. 
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For December 19, 2024

PLUR

Pluri Applauds Mesoblast For FDA Approval Of First Mesenchymal Stromal Cell Therapy For Steroid-Refractory Acute Graft-Versus-Host Disease, Highlighting Regenerative Medicine's Transformative Potential And Advancing MSC Therapies In Healthcare

- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer -
- Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 -
CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation of its Pancreatic Cancer Advisory Board. The advisory board, which comprises world-renowned oncology clinical researchers, will provide strategic medical and clinical guidance to the company as its pipeline, including lead clinical program IMM-1-104, continues to advance.

Biotech

Management

General

IMRX

Immuneering Launches Pancreatic Cancer Advisory Board; Establishment Reflects The Clinical Progress Of IMM-1-104 And Its Promise In Pancreatic Cancer

WestPark Capital analyst Casey Ryan initiates coverage on Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) with a Buy rating and announces Price Target of $1.3.

Initiation

MVIS

WestPark Capital Initiates Coverage On Microvision with Buy Rating, Announces Price Target of $1.3

CarMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) shares are trading higher after the company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42572355/carmax-reports-third-quarter-fiscal-year-2025-results" rel="noreferrer noopener">third-quarter earnings results</a>.
Quarterly sales of&nbsp;$6.223 billion&nbsp;beat the street view of&nbsp;$6.042 billion. The company reported earnings per share of 81 cents, beating the&nbsp;analyst <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus estimate of 64 cents</a>.
CarMax Auto Finance income was&nbsp;$159.9&nbsp;million, an increase of 7.6%&nbsp;year over year, driven by an improvement in CAF&#8217;s net interest margin percentage and higher average managed receivables.
The provision for loan losses was consistent with expectations set at the end of the second quarter of this year.
Retail used unit sales rose by&nbsp;5.4% Y/Y, comparable store used unit sales increased by&nbsp;4.3%&nbsp;Y/Y and wholesale units increased&nbsp;6.3% Y/Y.
Gross profit per retail used unit was&nbsp;$2,306 (flat Y/Y), and gross profit per wholesale unit was&nbsp;$1,015 (up $54 per unit Y/Y). The Extended Protection Plan margin increased by&nbsp;$53&nbsp;per retail unit to&nbsp;$573.
In the third quarter of fiscal year 2025, the company repurchased 1.5 million shares of common stock for $114.8 million. As of November 30, 2024, the company had $2.04 billion remaining available for repurchase under the outstanding authorization.
The company exited the quarter with cash and equivalents worth&nbsp;$271.9 million. Restricted cash from collections on auto loans receivable totaled $541.15 million. Inventories at quarter-end was&nbsp;$3.665 billion.
Bill Nash, president and chief executive officer, said, &#8221;Our solid execution and a more stable environment for vehicle valuations enabled us to deliver robust EPS growth driven by increases in unit sales and buys, solid margins, growth in CAF income, and ongoing management of SG&amp;A.&#8221;&nbsp;
During the&nbsp;third quarter&nbsp;of fiscal 2025, the company opened one new store in Alliance, Texas.
Investors can gain exposure to the stock via Valued Advisers Trust Kovitz Core Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQTY#NYSE">EQTY</a>) and Invesco Bloomberg Analyst Rating Improvers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPGD#NYSE">UPGD</a>).
Price Action: KMX shares are trading higher by 6.44% to $86.66 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42569970/carmax-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts" target="_blank" rel="noreferrer noopener">CarMax Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock.

Earnings

Equities

Large Cap

Topics

EQTY

UPGD

CarMax Q3 Earnings: Solid Growth In Auto Finance Income, Retail And Wholesale Units

Aquestive Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the U.S. Food and Drug Administration (FDA) has granted seven years of orphan drug exclusivity (ODE) to Libervant&#xAE; (diazepam) Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy between two to five years of age. On April 26, 2024, Libervant&#xAE; (diazepam) Buccal Film was approved for pediatric patients between two to five years of age. FDA granted ODE based on their assessment that Libervant's buccal route of administration provides a major contribution to patient care over the rectal route of administration by providing a significantly improved ease of use.&nbsp;

AQST

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity For Libervant Buccal Film In Pediatric Patients With Seizure Clusters Ages 2-5

Opus Genetics Secures FDA Agreement Under Special Protocol Assessment For Phase 3 Trial Of Oral APX3330 In Diabetic Retinopathy, Targeting Reduction In Disease Progression With NDA Submission Planned Upon Successful Trial Outcome

—Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026—
—Additional equity investment raises Gilead's ownership stake in Assembly Bio to 29.9%—
–Funding supports pipeline progress, including amendment to accelerate clinical development of Assembly Bio's novel small molecule hepatitis D virus candidate ABI-6250—
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced an equity investment of $20.1 million by Gilead Sciences, Inc. ("Gilead") to purchase additional Assembly Bio common stock and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. With the new equity investment, Gilead increases its equity ownership of Assembly Bio to 29.9%.
Funding received from Gilead will support the advancement of Assembly Bio's clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus (HDV) and hepatitis B virus (HBV). Assembly Bio expects to release data from multiple ongoing clinical studies in the coming year, including the interim Phase 1b proof-of-concept data readout for ABI-5366 projected for the first half of 2025.
The amendment to the collaboration agreement adjusts the option timepoints and option payment structure for ABI-6250, an orally bioavailable viral entry inhibitor for the treatment of HDV, to support updated clinical strategies to accelerate and optimize program development. As part of this amendment, $10 million of option-related payments for this program have been accelerated.

Contracts

ASMB

GILD

Assembly Biosciences Announces $30.1M Equity Investment And Accelerated Funding From Gilead To Advance Clinical Development Programs; Additional Equity Investment Raises Gilead's Ownership Stake In Assembly Bio To 29.9%

QNRX

Quoin Pharmaceuticals Receives FDA Clearance To Initiate A New QRX003 Netherton Syndrome Clinical Study

Goldman Sachs analyst Mark Delaney maintains Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) with a Buy and raises the price target from $145 to $160.

Goldman Sachs Maintains Buy on Jabil, Raises Price Target to $160

UAVS

AgEagle Aerial Systems Secures Largest Sensor Order In Company History With Milestone Sale Of 60 RedEdge-P Multispectral Sensors To East Asian Reseller, Highlighting 2024 Growth And Focus On Long-Term Shareholder Value

– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier –
– Maximal TYK2 inhibition achieved with favorable pharmacokinetic profile in CNS and periphery –
– Data support advancement to Phase 2 clinical trial in multiple sclerosis, anticipated in 2H 2025 –
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced positive data from a Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-ascending doses of A-005, a potent, selective, central nervous system (CNS) penetrant TYK2 inhibitor, in healthy participants.

ALMS

Alumis Announces Phase 1 Data For CNS Penetrant TYK2 Inhibitor, A-005; A-005 Was Well Tolerated And Demonstrated Ability To Cross Blood-Brain Barrier

Rosenblatt analyst Kevin Cassidy maintains Penguin Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) with a Buy and maintains $27 price target.

Penguin Solutions, Inc. - Ordinary Shares

PENG

Rosenblatt Maintains Buy on Penguin Solutions, Maintains $27 Price Target

Agreement&nbsp;Reached on Primary Endpoint and Phase 3 Trial Design
Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering
FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRD#NASDAQ">IRD</a>), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small-molecule drugs to treat other ophthalmologic disorders, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 clinical trial evaluating oral APX3330 for the treatment of moderate to severe non-proliferative diabetic retinopathy (NPDR).
The SPA agreement reflects that the proposed Phase 3 trial design, endpoints, and planned analyses will be adequate to support a New Drug Application (NDA) submission for treatment of NPDR, subject to a successful outcome of the trial and review of all data in the NDA. The agreed primary endpoint is a reduction in 3-step or greater worsening on the binocular diabetic retinopathy severity scale (DRSS) score, compared to placebo. In the previous Phase 2 ZETA-1 trial, oral APX3330 showed the potential to slow or prevent clinically meaningful progression of DR and demonstrated a favorable safety profile.

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment For Phase 3 Trial Of APX3330 In Diabetic Retinopathy; Agreement Reached On Primary Endpoint And Phase 3 Trial Design

Backed By Data From Transpher A Study Showing Sustained Cognitive Improvements And Mild Adverse Events

RARE

Ultragenyx Submits Biologics License Application To FDA For UX111 AAV Gene Therapy Seeking Accelerated Approval For Sanfilippo Syndrome Type A Treatment

GXAI

Gaxos.ai Announces $5M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules; Totaling 1.45M Shares At $3.32 Per Share, Closing Expected By Dec. 20, 2024

Graphite Miners News For The Month Of November 2024

NOVONIX Ltd (AU:NVX) has released an update. Phillips 66 Company (P66) has reduced its voting power in Novonix Limited from 16.16% to 13.75% due to...

Phillips 66 Adjusts Stake in Novonix Limited

NOVONIX (NVX) and Gamry Instruments announced a strategic collaboration that will allow for the integration of a Gamry EIS box with a NOVONIX Ultra...

Novonix enters collaboration with Gamry Instruments

NOVONIX Ltd (AU:NVX) has released an update. Novonix Ltd recently held an Investor Day, highlighting its strategic initiatives and growth plans in ...

Novonix Outlines Growth Strategy Amid Rising Battery Demand

NOVONIX Ltd (AU:NVX) has released an update. NOVONIX Ltd has announced the cessation of 724,205 performance rights as the conditions for these secu...

NOVONIX Ltd Announces Cessation of Securities

NOVONIX Ltd (AU:NVX) has released an update. NOVONIX Limited has announced the issuance of 211,129 performance rights under an employee incentive s...

NOVONIX Issues Unquoted Performance Rights to Employees

Novonix (NVX) "announced a conditional commitment to NOVONIX through one if its wholly-owned U.S.-based subsidiaries, from the U.S. Department of E...

Novonix offered conditional commitment for $754M DoE loan for new facility

Graphite miners seek 920% tariff on Chinese imports of battery material

Novonix (NVX) announced the company's participation in the American Active Anode Material Producers', or AAAMP, petition to the U.S. Department of ...

Novonix announces participation in AAAMP petition

NOVONIX Ltd (AU:NVX) has released an update. NOVONIX Ltd has joined a coalition of American graphite producers in filing a trade case against China...

NOVONIX Joins Trade Case Against Chinese Graphite Practices

AMVMF

APMFF

BSSMF

CBULF

CYLYF

DMNKF

ECGFF

ECORF

EVMIF

FCSMF

FGPHF

GBMIF

GEMSF

GPHOF

GRFX

GRFXF

IMYSF

IMYSY

JRVMF

LEMIF

LMRMF

MGPHF

MNSEF

NGPHF

NNXPF

NSRCF

NVNXF

RFLXF

SGLFF

SRHYY

STSBF

SVMLF

SYAAF

TLGRF

TORVF

ZTEK

Press Releases

NOVONIX Announces Participation in the H.C. Wainwright Conference

NOVONIX to Host Third Quarter 2024 Operations Update and Participate in OTC Small Cap Growth Conference

Voltaiq and NOVONIX Announce Strategic Partnership to Drive Efficiency and Quality in the Battery Industry

NOVONIX and ICoNiChem Enter into Collaboration Agreement Focused on Sustainable Cathode Material Feedstock

NOVONIX and Stellantis Sign Binding Offtake Agreement

NOVONIX and PowerCo SE Sign Binding Offtake Agreement

NOVONIX Announces December Investor Events

NOVONIX Announces Electrochemical Impedance Spectroscopy Partnership with Gamry Instruments Inc.

Financing

NOVONIX Offered Conditional Commitment for US$754 Million Loan from the U.S. Department of Energy for New Synthetic Graphite Manufacturing Plant in Tennessee

American Graphite Producers File Trade Case with U.S. Government Over Anticompetitive Graphite Prices on Chinese Exports

NOVONIX

Comments

NOVONIX

매도 수량

NOVONIX (OTC:NVNXF) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌